Details of the Drug Combination

General Information of Drug Combination (ID: DCKTT31)

Drug Combination Name
Allopurinol Colchicine
Indication
Disease Entry Status REF
Gout Phase 4 [1]
Component Drugs Allopurinol   DMLPAOB Colchicine   DM2POTE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Allopurinol
Disease Entry ICD 11 Status REF
Gout FA25 Approved [2]
Hyperuricaemia 5C55.Y Approved [3]
Recurrent adult burkitt lymphoma 2A85.6 Approved [2]
Allopurinol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Xanthine dehydrogenase/oxidase (XDH) TT7RJY8 XDH_HUMAN Inhibitor [9]
------------------------------------------------------------------------------------
Allopurinol Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [10]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Allopurinol Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
RNA cytidine acetyltransferase (hALP) DEZV4AP NAT10_HUMAN Metabolism [12]
------------------------------------------------------------------------------------
Allopurinol Interacts with 30 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Increases Transport [13]
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Increases Response To Substance [14]
HLA class I histocompatibility antigen, C alpha chain (HLA-C) OTV38BUJ HLAC_HUMAN Increases ADR [15]
HLA class I histocompatibility antigen, A alpha chain (HLA-A) OTAH14LU HLAA_HUMAN Increases ADR [16]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1) OTVVI3UI DQB1_HUMAN Increases ADR [15]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Decreases Expression [17]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) OTY9R6FZ ERN1_HUMAN Increases Expression [18]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases Expression [19]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [20]
Apolipoprotein C-III (APOC3) OTW3520C APOC3_HUMAN Decreases Expression [18]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Expression [18]
Protein disulfide-isomerase (P4HB) OTTYNYPF PDIA1_HUMAN Decreases Expression [18]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [21]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [21]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [18]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Expression [20]
Platelet glycoprotein 4 (CD36) OT5CZWKY CD36_HUMAN Decreases Expression [18]
Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF6) OTAFHAVI ATF6A_HUMAN Increases Expression [18]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [20]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [20]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [18]
Microsomal triglyceride transfer protein large subunit (MTTP) OTNUVSDT MTP_HUMAN Decreases Expression [18]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Increases Expression [22]
Peroxisome proliferator-activated receptor alpha (PPARA) OTK095PP PPARA_HUMAN Increases Expression [22]
Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) OTM0A0DY ACOX1_HUMAN Increases Expression [22]
Angiopoietin-related protein 3 (ANGPTL3) OTCD5Z9W ANGL3_HUMAN Decreases Expression [18]
Glycophorin-A (GYPA) OTABU4YV GLPA_HUMAN Increases ADR [23]
Myeloperoxidase (MPO) OTOOXLIN PERM_HUMAN Increases ADR [23]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Increases ADR [23]
HLA class I histocompatibility antigen protein P5 (HCP5) OTV0YRI8 HCP5_HUMAN Increases ADR [24]
------------------------------------------------------------------------------------
⏷ Show the Full List of 30 DOT(s)
Indication(s) of Colchicine
Disease Entry ICD 11 Status REF
Acute gout flare FA25.0 Approved [4]
Acute gouty arthritis FA25.0 Approved [5]
Gout FA25 Approved [6]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [7]
Familial Mediterranean fever N.A. Investigative [6]
Colchicine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Binder [26]
------------------------------------------------------------------------------------
Colchicine Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [27]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [28]
------------------------------------------------------------------------------------
Colchicine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [29]
------------------------------------------------------------------------------------
Colchicine Interacts with 117 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [30]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [31]
Succinate dehydrogenase assembly factor 1, mitochondrial (SDHAF1) OTDG5VW7 SDHF1_HUMAN Decreases Expression [25]
Serine/threonine-protein kinase Sgk1 (SGK1) OT301T1U SGK1_HUMAN Decreases Expression [25]
E3 ubiquitin-protein ligase TRIM38 (TRIM38) OT6SP1M9 TRI38_HUMAN Decreases Expression [25]
Torsin-1A (TOR1A) OTYCLGJU TOR1A_HUMAN Decreases Expression [25]
Ectoderm-neural cortex protein 1 (ENC1) OTJEUB6U ENC1_HUMAN Decreases Expression [25]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Decreases Expression [25]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) OT9RDS3H IKKB_HUMAN Increases Phosphorylation [32]
Plexin-B2 (PLXNB2) OT56I2VD PLXB2_HUMAN Decreases Expression [25]
Protein phosphatase 1D (PPM1D) OT8NLZ9D PPM1D_HUMAN Decreases Expression [25]
Regulator of G-protein signaling 16 (RGS16) OTBKZASI RGS16_HUMAN Decreases Expression [25]
E3 ubiquitin-protein ligase RNF113A (RNF113A) OTR6N7HU R113A_HUMAN Decreases Expression [25]
DNA repair protein RAD51 homolog 3 (RAD51C) OTUD6SY5 RA51C_HUMAN Decreases Expression [25]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1) OTEAUJXN TRIA1_HUMAN Decreases Expression [25]
Dual specificity protein phosphatase 14 (DUSP14) OTGODFCR DUS14_HUMAN Decreases Expression [25]
Kinesin-like protein KIF20A (KIF20A) OTXOQHE0 KI20A_HUMAN Decreases Expression [25]
CUGBP Elav-like family member 2 (CELF2) OTLJJ4VT CELF2_HUMAN Increases Expression [33]
G1/S-specific cyclin-E2 (CCNE2) OTBBUKQQ CCNE2_HUMAN Decreases Expression [25]
Prothrombin (F2) OTNFSM49 THRB_HUMAN Affects Activity [34]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [35]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [36]
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Expression [34]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Increases Activity [37]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [38]
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Decreases Expression [39]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [40]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [36]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [41]
Microtubule-associated protein tau (MAPT) OTMTP2Z7 TAU_HUMAN Decreases Expression [42]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [43]
Microtubule-associated protein 2 (MAP2) OT6UYT3X MTAP2_HUMAN Decreases Expression [44]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Affects Activity [45]
CD59 glycoprotein (CD59) OTSUMQDH CD59_HUMAN Increases Mutagenesis [46]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Increases Expression [47]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Expression [40]
Tyrosine aminotransferase (TAT) OT2CJ91O ATTY_HUMAN Decreases Expression [48]
Syndecan-1 (SDC1) OTWKRVZC SDC1_HUMAN Decreases Expression [25]
Lactoperoxidase (LPO) OTJ9QKX9 PERL_HUMAN Decreases Expression [44]
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Increases Activity [49]
NADPH:adrenodoxin oxidoreductase, mitochondrial (FDXR) OTPDCK1F ADRO_HUMAN Decreases Expression [25]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Decreases Expression [25]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Phosphorylation [32]
M-phase inducer phosphatase 1 (CDC25A) OTSLKKCO MPIP1_HUMAN Decreases Expression [25]
GTP cyclohydrolase 1 (GCH1) OTOZ6NSL GCH1_HUMAN Decreases Expression [25]
Sodium-dependent serotonin transporter (SLC6A4) OT6FGDLW SC6A4_HUMAN Decreases Expression [44]
Replication factor C subunit 1 (RFC1) OT3L5PK3 RFC1_HUMAN Decreases Expression [25]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [43]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Decreases Activity [50]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [25]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9) OTV9L89D TNFL9_HUMAN Decreases Expression [25]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Expression [44]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [41]
RNA-binding protein 34 (RBM34) OTX3LUGI RBM34_HUMAN Decreases Expression [25]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Phosphorylation [38]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Increases Phosphorylation [38]
LIM/homeobox protein Lhx2 (LHX2) OTK61NP8 LHX2_HUMAN Decreases Expression [25]
DNA mismatch repair protein Msh6 (MSH6) OT46FP09 MSH6_HUMAN Decreases Expression [25]
RecQ-like DNA helicase BLM (BLM) OTEJOAJX BLM_HUMAN Decreases Expression [25]
Ataxin-1 (ATXN1) OTQF0HNR ATX1_HUMAN Decreases Expression [25]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [41]
Interleukin-2 (IL2) OTGI4NSA IL2_HUMAN Decreases Expression [35]
Ras-related protein Rap-2b (RAP2B) OTD2NDQP RAP2B_HUMAN Decreases Expression [25]
Protein BTG1 (BTG1) OTVJ2CDM BTG1_HUMAN Decreases Expression [25]
Protein BTG2 (BTG2) OTZF6K1H BTG2_HUMAN Decreases Expression [25]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [25]
Myelin transcription factor 1 (MYT1) OTC3660I MYT1_HUMAN Increases Phosphorylation [50]
DNA-binding protein inhibitor ID-3 (ID3) OTUULW5Z ID3_HUMAN Decreases Expression [25]
Glutamate receptor ionotropic, NMDA 1 (GRIN1) OTZ5YBO8 NMDZ1_HUMAN Decreases Expression [44]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [41]
Tripartite motif-containing protein 26 (TRIM26) OTS0DJIP TRI26_HUMAN Decreases Expression [25]
E3 ubiquitin-protein ligase TRIM32 (TRIM32) OTJOV0PG TRI32_HUMAN Decreases Expression [25]
Chromatin assembly factor 1 subunit A (CHAF1A) OTXSSY4H CAF1A_HUMAN Decreases Expression [25]
Chromatin assembly factor 1 subunit B (CHAF1B) OTOMK4KH CAF1B_HUMAN Decreases Expression [25]
DNA topoisomerase 3-alpha (TOP3A) OT3CKUI9 TOP3A_HUMAN Decreases Expression [25]
Oligodendrocyte transcription factor 2 (OLIG2) OTMCN6D3 OLIG2_HUMAN Decreases Expression [44]
Protein BTG3 (BTG3) OT9ANHVT BTG3_HUMAN Decreases Expression [25]
Protein-tyrosine kinase 2-beta (PTK2B) OTGAS0I8 FAK2_HUMAN Increases Phosphorylation [33]
Histone RNA hairpin-binding protein (SLBP) OTVYYQRT SLBP_HUMAN Decreases Expression [25]
Nuclear factor of activated T-cells, cytoplasmic 4 (NFATC4) OTTDCUAO NFAC4_HUMAN Decreases Localization [51]
Neutral amino acid transporter B(0) (SLC1A5) OTE2H26Q AAAT_HUMAN Decreases Expression [25]
E3 ubiquitin-protein ligase RNF19B (RNF19B) OTYCWKBP RN19B_HUMAN Decreases Expression [25]
Protein MCM10 homolog (MCM10) OTV0O3JN MCM10_HUMAN Decreases Expression [25]
Partner and localizer of BRCA2 (PALB2) OT6DNDBG PALB2_HUMAN Decreases Expression [25]
E3 ubiquitin-protein ligase TRIM22 (TRIM22) OTJBLG5R TRI22_HUMAN Decreases Expression [25]
Leucine-rich repeat-containing protein 47 (LRRC47) OTSE8NAO LRC47_HUMAN Decreases Expression [25]
Protein tyrosine phosphatase type IVA 1 (PTP4A1) OTK0NFXJ TP4A1_HUMAN Decreases Expression [25]
Cytochrome c oxidase assembly factor 7 (COA7) OTRQJYL6 COA7_HUMAN Decreases Expression [25]
Mitochondrial potassium channel (CCDC51) OTOJNHNA MITOK_HUMAN Decreases Expression [25]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Increases Expression [47]
Integrator complex subunit 15 (INTS15) OT3O4INM INT15_HUMAN Decreases Expression [25]
Pleckstrin homology domain-containing family F member 1 (PLEKHF1) OT9OL16U PKHF1_HUMAN Decreases Expression [25]
Krueppel-like factor 6 (KLF6) OTQY9S7F KLF6_HUMAN Increases Expression [25]
Cell division control protein 6 homolog (CDC6) OTX93FE7 CDC6_HUMAN Decreases Expression [25]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Decreases Expression [25]
Protein orai-3 (ORAI3) OTUP3OH3 ORAI3_HUMAN Decreases Expression [25]
Protein pelota homolog (PELO) OTF3WLIM PELO_HUMAN Decreases Expression [25]
TIMELESS-interacting protein (TIPIN) OT9PZHXV TIPIN_HUMAN Decreases Expression [25]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [17]
tRNA pseudouridine(38/39) synthase (PUS3) OT6WG6M2 PUS3_HUMAN Decreases Expression [25]
Transmembrane protein 185B (TMEM185B) OTGNYS0J T185B_HUMAN Decreases Expression [25]
Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2) OT3Q11WQ I20L2_HUMAN Decreases Expression [25]
GrpE protein homolog 1, mitochondrial (GRPEL1) OT8O00YJ GRPE1_HUMAN Decreases Expression [25]
p53-induced death domain-containing protein 1 (PIDD1) OTWFM930 PIDD1_HUMAN Decreases Expression [25]
Fructose-2,6-bisphosphatase TIGAR (TIGAR) OTR7NMRJ TIGAR_HUMAN Decreases Expression [25]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Decreases Expression [25]
Forkhead box protein J2 (FOXJ2) OTPT639J FOXJ2_HUMAN Decreases Expression [25]
Homologous-pairing protein 2 homolog (PSMC3IP) OT9UB5UO HOP2_HUMAN Decreases Expression [25]
Protein CLN8 (CLN8) OT0D4CB5 CLN8_HUMAN Decreases Expression [25]
rRNA methyltransferase 2, mitochondrial (MRM2) OTRYA1HU MRM2_HUMAN Decreases Expression [25]
Frizzled-1 (FZD1) OTZATHVS FZD1_HUMAN Decreases Expression [25]
SH3 and multiple ankyrin repeat domains protein 2 (SHANK2) OTSQTPFQ SHAN2_HUMAN Decreases Expression [44]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) OT1OG4QZ AAKB1_HUMAN Decreases Expression [25]
Pleckstrin homology-like domain family A member 3 (PHLDA3) OTXFUDO2 PHLA3_HUMAN Decreases Expression [25]
Sestrin-1 (SESN1) OTSFDZWL SESN1_HUMAN Decreases Expression [25]
RalA-binding protein 1 (RALBP1) OTBIGB1D RBP1_HUMAN Affects Transport [52]
ATP-binding cassette sub-family A member 13 (ABCA13) OTTHTUQN ABCAD_HUMAN Affects Response To Substance [53]
------------------------------------------------------------------------------------
⏷ Show the Full List of 117 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Gout DCVDTLX N. A. Phase 2 [54]
Intercritical Gout DCW593F N. A. Phase 1 [55]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04875702) Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
2 Allopurinol FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6795).
4 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 022351
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7526).
6 Colchicine FDA Label
7 ClinicalTrials.gov (NCT04322565) Colchicine Counteracting Inflammation in COVID-19 Pneumonia. U.S. National Institutes of Health.
8 Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010 Jan;3(1):73-81.
9 Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
10 Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14.
11 Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83.
12 Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol. 1999 Jan;54(11):869-76.
13 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
14 HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4134-9. doi: 10.1073/pnas.0409500102. Epub 2005 Mar 2.
15 A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet. 2011 Aug;38(4):303-9. doi: 10.1111/j.1744-313X.2011.01011.x. Epub 2011 May 4.
16 Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011 May;21(5):303-7. doi: 10.1097/FPC.0b013e32834282b8.
17 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
18 Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
19 Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
20 Allopurinol induces innate immune responses through mitogen-activated protein kinase signaling pathways in HL-60 cells. J Appl Toxicol. 2016 Sep;36(9):1120-8. doi: 10.1002/jat.3272. Epub 2015 Dec 7.
21 Systemic drugs inducing non-immediate cutaneous adverse reactions and contact sensitizers evoke similar responses in THP-1 cells. J Appl Toxicol. 2015 Apr;35(4):398-406. doi: 10.1002/jat.3033. Epub 2014 Aug 4.
22 Allopurinol Protects Against Cholestatic Liver Injury in Mice Not Through Depletion of Uric Acid. Toxicol Sci. 2021 May 27;181(2):295-305. doi: 10.1093/toxsci/kfab034.
23 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
24 Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013 Feb;93(2):153-8. doi: 10.1038/clpt.2012.209. Epub 2012 Oct 17.
25 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
26 Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
27 Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53.
28 Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61.
29 Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9.
30 Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol. 2004 Dec;66(6):1397-405. doi: 10.1124/mol.104.005009. Epub 2004 Sep 1.
31 Functional analysis of MRP1 cloned from bovine. FEBS Lett. 2002 Jun 19;521(1-3):211-3. doi: 10.1016/s0014-5793(02)02816-8.
32 Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J Neurochem. 2006 Oct;99(2):402-15. doi: 10.1111/j.1471-4159.2006.04005.x.
33 Discovery of a novel compound: insight into mechanisms for acrylamide-induced axonopathy and colchicine-induced apoptotic neuronal cell death. Brain Res. 2001 Aug 3;909(1-2):8-19. doi: 10.1016/s0006-8993(01)02608-7.
34 [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
35 Serum interleukin-2 and tumor necrosis factor-alpha in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4. Am J Gastroenterol. 1992 Apr;87(4):465-70.
36 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
37 Comparative effects of microtubules disruption on glucocorticoid receptor functions in proliferating and quiescent cells. Int J Toxicol. 2010 May-Jun;29(3):326-35. doi: 10.1177/1091581810366486.
38 Nocodazole-induced p53-dependent c-Jun N-terminal kinase activation reduces apoptosis in human colon carcinoma HCT116 cells. J Biol Chem. 2002 Nov 15;277(46):43648-58. doi: 10.1074/jbc.M203214200. Epub 2002 Sep 6.
39 The stability of cytokeratin 18 in human liver cells during colchicine-induced microtubule disruption. Food Chem Toxicol. 2001 Jan;39(1):85-9. doi: 10.1016/s0278-6915(00)00113-7.
40 Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
41 Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
42 Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
43 High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol. 2017 Mar;91(3):1367-1383. doi: 10.1007/s00204-016-1781-0. Epub 2016 Jun 29.
44 Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
45 Induced differentiation in HT29, a human colon adenocarcinoma cell line. J Cell Sci. 1999 Aug;112 ( Pt 16):2657-66. doi: 10.1242/jcs.112.16.2657.
46 Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay. Mutat Res. 2006 Dec 1;602(1-2):14-25. doi: 10.1016/j.mrfmmm.2006.07.009. Epub 2006 Oct 11.
47 Synthesis and antitumor evaluation of nitrovinyl biphenyls: anticancer agents based on allocolchicines. ChemMedChem. 2011 May 2;6(5):859-68. doi: 10.1002/cmdc.201100019. Epub 2011 Apr 6.
48 Microtubule disarray in primary cultures of human hepatocytes inhibits transcriptional activity of the glucocorticoid receptor via activation of c-jun N-terminal kinase. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004 Dec;148(2):135-9.
49 Dihydroactinidiolide regulates Nrf2/HO-1 expression and inhibits caspase-3/Bax pathway to protect SH-SY5Y human neuroblastoma cells from oxidative stress induced neuronal apoptosis. Neurotoxicology. 2021 May;84:53-63. doi: 10.1016/j.neuro.2021.02.006. Epub 2021 Feb 20.
50 Involvement of cytoskeleton in AhR-dependent CYP1A1 expression. Curr Drug Metab. 2006 Apr;7(3):301-13. doi: 10.2174/138920006776359310.
51 Zinc and the cytoskeleton in the neuronal modulation of transcription factor NFAT. J Cell Physiol. 2007 Jan;210(1):246-56. doi: 10.1002/jcp.20861.
52 RLIP76 (RALBP1)-mediated transport of leukotriene C4 (LTC4) in cancer cells: implications in drug resistance. Int J Cancer. 2004 Dec 20;112(6):934-42. doi: 10.1002/ijc.20516.
53 Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.
54 ClinicalTrials.gov (NCT02063997) Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
55 ClinicalTrials.gov (NCT01451645) Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol